+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Goiter Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102563
Goiter is characterized by the enlargement of the thyroid gland. It affects around 2.2 billion people worldwide, with iodine deficiency reported as the most common cause of the disease. In the United States, goiter affects 5% of the population.

Goiter Epidemiology Forecast Report Coverage

The “Goiter Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of goiter. It projects the future incidence and prevalence rates of Goiter across various populations. The study covers age, gender, and type as major determinants of the goiter-affected population. The report highlights patterns in the prevalence of goiter over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of goiter in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Goiter Disease Overview

Goiter or goitre occurs when the thyroid gland grows larger. There are several possible causes of goiter which may or may not be linked with abnormal levels of thyroid hormone. Goiter is classified into simple (diffuse) goiter, nodular goiter, and multinodular goiter, depending on how it enlarges. In simple (diffuse) goiter, the entire thyroid gland swells whereas in nodular goiter, a solid or fluid-filled lump called a nodule is formed within the thyroid. People with insulin resistance, metabolic syndrome, or obesity have a higher likelihood of developing goiter.

Goiter: Treatment Overview

Treatment is focused on how large the thyroid gland has grown, the severity of symptoms, and the underlying causes. If hypothyroidism or underactive thyroid is causing goiter then medications such as Levothyroxine (Levothroid®, Synthroid®) are prescribed. In hyperthyroidism or overactive thyroid cases, methimazole (Tapazole®) and propylthiouracil are typically used. Aspirin or a corticosteroid medication is generally taken if inflammation is the reason behind goiter.

Epidemiology

The goiter epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for goiter by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for goiter and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
  • An estimated 2.2 billion individuals are affected by goiter, with iodine deficiency being the most common cause worldwide. In the United States, around 5% of people have goiter.
  • Studies reveal that the incidence and prevalence of goiter depends on the degree of iodine deficiency. In cases of mild iodine deficiency, the incidence of goiter ranges from 5 to 20%. The prevalence increases to 20-30% in moderate iodine deficiency and more than 30% in severe iodine deficiency.
  • Goiter is relatively common in people over 40 years of age. People assigned female at birth are nearly 4 times more likely to develop the condition compared to people assigned male at birth.
  • Some studies have suggested that children with excess iodine intake have over 5% risk of developing goiter.

Country-wise Goiter Epidemiology

The goiter epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of goiter varies between countries owing to the differences in factors such as iodine intake, dietary habits, genetic predisposition, and access to healthcare. According to the National Family Health Survey IV [NFHS IV (2015-2016)], the prevalence of self-reported goiter or thyroid disorder in India was 2.2% whereas NFHS-V (2019-2021) reported the prevalence to be 2.9%.

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of goiter based on several factors.
  • Goiter Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population and the unmet needs of goiter are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of goiter epidemiology in the 8 major markets?
  • What will be the total number of patients with goiter across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of goiter in the 8 major markets in the historical period?
  • Which country will have the highest number of goiter patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of goiter during the forecast period of 2025-2034?
  • What are the currently available treatments for goiter?
  • What are the disease risks, signs, symptoms, and unmet needs of goiter?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Goiter Market Overview - 8 MM
3.1 Goiter Market Historical Value (2018-2024)
3.2 Goiter Market Forecast Value (2025-2034)
4 Goiter Epidemiology Overview - 8 MM
4.1 Goiter Epidemiology Scenario (2018-2024)
4.2 Goiter Epidemiology Forecast (2025-2034)
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
5.7 Types of Goiter
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM (218-2034)
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Diagnosed Prevalent Cases of Goiter
7.4 Type-Specific Cases of Goiter
7.5 Gender-Specific Cases of Goiter
7.6 Age-Specific Cases of Goiter
8 Epidemiology Scenario and Forecast: United States (218-2034)
8.1 Assumptions and Rationale in the US
8.2 Diagnosed Prevalent Cases of Goiter in the US
8.3 Type-Specific Cases of Goiter in the US
8.4 Gender-Specific Cases of Goiter in the US
8.5 Age-Specific Cases of Goiter in the US
9 Epidemiology Scenario and Forecast: United Kingdom (218-2034)
9.1 Assumptions and Rationale in United Kingdom
9.2 Diagnosed Prevalent Cases of Goiter in United Kingdom
9.3 Type-Specific Cases of Goiter in United Kingdom
9.4 Gender-Specific Cases of Goiter in United Kingdom
9.5 Age-Specific Cases of Goiter in United Kingdom
10 Epidemiology Scenario and Forecast: Germany (218-2034)
10.1 Assumptions and Rationale in Germany
10.2 Diagnosed Prevalent Cases of Goiter in Germany
10.3 Type-Specific Cases of Goiter in Germany
10.4 Gender-Specific Cases of Goiter in Germany
10.5 Age-Specific Cases of Goiter in Germany
11 Epidemiology Scenario and Forecast: France (218-2034)
11.1 Assumptions and Rationale in France
11.2 Diagnosed Prevalent Cases of Goiter in France
11.3 Type-Specific Cases of Goiter in France
11.4 Gender-Specific Cases of Goiter in France
11.5 Age-Specific Cases of Goiter in France
12 Epidemiology Scenario and Forecast: Italy (218-2034)
12.1 Assumptions and Rationale in Italy
12.2 Diagnosed Prevalent Cases of Goiter in Italy
12.3 Type-Specific Cases of Goiter in Italy
12.4 Gender-Specific Cases of Goiter in Italy
12.5 Age-Specific Cases of Goiter in Italy
13 Epidemiology Scenario and Forecast: Spain (218-2034)
13.1 Assumptions and Rationale in Spain
13.2 Diagnosed Prevalent Cases of Goiter in Spain
13.3 Type-Specific Cases of Goiter in Spain
13.4 Gender-Specific Cases of Goiter in Spain
13.5 Age-Specific Cases of Goiter in Spain
14 Epidemiology Scenario and Forecast: Japan (218-2034)
14.1 Assumptions and Rationale in Japan
14.2 Diagnosed Prevalent Cases of Goiter in Japan
14.3 Type-Specific Cases of Goiter in Japan
14.4 Gender-Specific Cases of Goiter in Japan
14.5 Age-Specific Cases of Goiter in Japan
15 Epidemiology Scenario and Forecast: India (218-2034)
15.1 Assumptions and Rationale in India
15.2 Diagnosed Prevalent Cases of Goiter in India
15.3 Type-Specific Cases of Goiter in India
15.4 Gender-Specific Cases of Goiter in India
15.5 Age-Specific Cases of Goiter in India
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights